Endoscopic treatment of Barrett’s neoplasia and gastric cancer: Standards and new developments
Gastroenterologie, ISSN: 2731-7439, Vol: 18, Issue: 3, Page: 186-195
2023
- 5Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures5
- Readers5
Article Description
Endoscopic therapy of Barrett’s neoplasia and gastric cancer represents the current therapeutic standard in early stages of the disease. Endoscopic detection by high-resolution white light endoscopy with the aid of chromoendoscopy is crucial. Resectability is then assessed based on the mucosal surface pattern and vascular structure, as these allow prediction of malignancy and depth of invasion. Treatment of Barrett’s neoplasia then follows a two-stage concept. In the first step, complete endoscopic resection by endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) for larger lesions is performed. Endoscopic resection is used as both a diagnostic (histology, staging with depth extension) and therapeutic procedure. After curative endoscopic resection of a Barrett’s neoplasm, radiofrequency ablation (RFA) of the remaining nonneoplastic Barrett’s mucosa is then indicated as a second step to prevent metachronous neoplasia. Subsequently, endoscopic surveillance is required. For the treatment of early gastric cancer, ESD is the procedure of choice based on the guideline due to higher R0 and en bloc resection rates compared to EMR. After curative endoscopic resection, unlike after surgical therapy with gastrectomy, structured endoscopic follow-up is required due to a significant risk of metachronous gastric cancer.
Bibliographic Details
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know